Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials

Cancer Journal from Scientific American

Volumn 4, Issue 3, 1998, Pages 194-203

  Jaffee, Elizabeth M ^a   Schutte, Mieke ^a   Gossett, Jeanette ^a   Morsberger, Laura A ^a   Adler, Adam J ^a   Thomas, Matthew ^a   Greten, Tim F ^a   Hruban, Ralph H ^a   Yeo, Charles J ^a   Griffin, Constance A ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Allogeneic tumor vaccines; Gene therapy; Pancreatic cancer cell lines; Tumor vaccines

Indexed keywords

CANCER VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HUMAN INSULIN; SOMATOMEDIN; SOMATOMEDIN B; SOMATOMEDIN C;

ANTIGEN PRESENTATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNIZATION; CANCER RESISTANCE; GENE MUTATION; GENETIC ENGINEERING; HUMAN; IMMUNOGENICITY; NONHUMAN; ONCOGENE K RAS; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; VACCINE PRODUCTION;

ADENOCARCINOMA; CANCER VACCINES; EPITHELIAL CELLS; GENES, RAS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; KARYOTYPING; KERATINS; MUTATION; PANCREATIC NEOPLASMS; STAINING AND LABELING; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0031861172     PISSN: 10814442     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Chen L, Linsley PS, Hellstrom KE. Costimulation of T cells for tumor immunity. Immunol Today 1993;14:483-486.
2. Pardoll DM. Paracrine cytokine adjuvants in cancer immunotherapy. Annu Rev Immunol 1995;13:399-415.
3. Dranoff G, Jaffee EM, Lazenby A et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte/macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Nad Acad Sci USA 1993; 90:3539-3543.
4. Huang AY, Golumbek P, Ahmadzadeh M et al. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 1994;264:961-965.
5. Jaffee EM, Pardoll DM. Gene therapy: its potential applications in the treatment of renal-cell carcinoma. Semin Oncol 1995;22: 81-91.
6. Simons JW, Jaffee EM, Weber CE et al. Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte/macrophage colony-stimulating factor gene transfer. Cancer Res 1997;5:1537-1546.
7. Boring CC, Squires TS, Tong T. Cancer statistics. Cancer 1991; 41:19-36.
8. Ikeda Y, Ezaki M, Hayashi I et al. Establishment and characterization of human pancreatic cancer cell lines in tissue culture and in nude mice. Jpn J Cancer Res 1990;81:987-993.
9. Elsasser H-P, Lehr U, Agricola B et al. Establishment and characterisation of two cell lines with different grade of differentiation derived from one primary human pancreatic adenocarcinoma. Virchows Archiv [B] 1992;61:295-306.
10. Kobari M, Hisano H, Matsuno S et al. Establishment of six human pancreatic cancer cell lines and their sensitivities to anti-tumor drugs. Tohoku J Exp Med 1986;150:231-248.
11. Bleday R, Tzanakakis GN, Schwalke MA et al. Epidermal growth factor stimulation and metastatic rate in human pancreatic carcinoma cell lines. J Surg Res 1990;49:276-279.
12. Silberberg JM, Gordon S, Zucker S. Identification of tissue factor in two human pancreatic cancer cell lines. Cancer Res 1989;49: 5443-5447.
13. Kyriazis AP, McCombs WB III, Sandberg AA et al. Establishment and characterization of human pancreatic adenocarcinoma cell line SW-1990 in tissue culture and the nude mouse. Cancer Res 1983;43:4393-4401.
14. Chang BK, Gutman R Chou T-C. Schedule-dependent interaction of α-difluoromethyl-ornithine and cis-dianninedichloroplatinum (II) against human and hamster pancreatic cancer cell lines. Cancer Res 1987;47:2247-2250.
15. Elsasser HP, MacDonald R, Dienst M et al. Characterization of a transglutaminase expressed in human pancreatic adenocarcinoma cells. Eur J Cell Biol 1993;61:321-328.
16. Suwa H, Yoshimura T, Yamaguchi N et al. K-ras and p53 alterations in genomic DNA and transcripts of human pancreatic adenocarcinoma cell lines. Jpn J Cancer Res 1994;85:1005-1014.
17. Lieber M, Mazzetta J, Nelson-Rees W et al. Establishment of a continuous tumor-cell line (Panc-1) from a human carcinoma of the exocrine pancreas. Int J Cancer 1975;15:741-747.
18. Jaffee EM, Dranoff G, Cohen LK et al. High efficiency gene transfer into primary human tumor explants without cell selection. Cancer Res 1993;53:2221-2226.
19. Caldos C, Hahn SA, Hruban RH et al. Detection of K-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia. Cancer Res 1994;54:3568-3573.
20. Hollstein MC, Metcalf RA, Welsh JA et al. Frequent mutation of the p53 gene in human esophageal cancer. Proc Natl Acad Sci USA 1990;87:9958-9961.
21. Griffin CA, Hruban RH, Morsberger LA et al. Consistent chromosome abnormalities in adenocarcinoma of the pancreas. Cancer Res 1995;55:2394-2399.
22. Cantrell MA, Anderson D, Cerretri DP et al. Cloning, sequence, and expression of a human granulocyte/macrophage colony-stimulating factor. Immunology 1985;82:6250-6254.
23. Holmes KL, Palaszynski E, Fredrickson TN et al. Correlation of cell-surface phenotype with the establishment of interleukin 3-dependent cell lines from wild-mouse murine leukemia virus-induced neoplasms. Proc Natl Acad Sci USA 1985;82:6687-6691.
24. Hruban RH, Van Mansfeld ADM, Offerhaus GJA et al. K-ras oncogene activation in adenocarcinoma of the pancreas. Am J Pathol 1993;143:545-554.
25. Cooper CS, Blair DG, Oskarsson MK et al. Characterization of human transforming genes from chemically transformed, teratocarcinoma, and pancreatic carcinoma cell lines. Cancer Res 1984;44:1-10.
26. Jaffee EM, Thomas MC, Huang AY et al. Enhanced immune priming with spatial distribution of paracrine cytokine vaccines. J Immunother Emphasis Tumor Immunol 1996;19:176-183.
27. Halaban R, Alfano FD. Selective elimination of fibroblasts from cultures of normal human melanocytes. In Vitro 1984;20:447-450.
28. Singer KH, Scearce RM, Tuck DT et al. Removal of fibroblasts from human epithelial cell cultures with use of a complement fixing monoclonal antibody reactive with human fibroblasts and monocytes/macrophages. J Invest Dermatol 1989;92:166-170.
29. Paraskeva C, Buckle BG, Thorpe PE. Selective killing of contaminating human fibroblasts in epithelial cultures derived from colorectal tumours using an and Thy-1 antibody-ricin conjugate. Br J Cancer 1985;51:131-134.
30. Boon T, van der Bruggen P. Human tumor antigens recognized by T lymphocytes. J Exp Med 1996;183:725-729.
31. Rosenberg SA, Kawakami Y, Robbins PF et al. Identification of the genes encoding cancer antigens: implications for cancer immunotherapy. Adv Cancer Res 1996;70:145-177.
32. Thomas MC, Greten TF, Pardoll DM et al. Enhanced tumor protection by GM-CSF expression at the site of an allogeneic vaccine. Submitted.
33. Gedde-Dahl T, Spurkland A, Fossum B et al. T cell epitopes encompassing the mutational hot spot position 61 of p21 ras: promiscuity in ras peptide binding to HLA. Eur J Immunol 1994; 24:410-414.
34. Jung S, Schluesener HJ. Human T lymphocytes recognize a peptide of single point mutated, oncogenic ras proteins. J Exp Med 1991;173:273-276.